NCT00911820View on ClinicalTrials.gov

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

August 31, 2013

Conditions
Esophageal CancerGastric CancerStomach Cancer
Interventions
DRUG

Bevacizumab

DRUG

Cisplatin

DRUG

Irinotecan

DEVICE

Docetaxel

Trial Locations (4)

37203

Sarah Cannon Research Institute, Nashville

75251

Texas Oncology Research, Dallas

02115

Dana-Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

SCRI Development Innovations, LLC

OTHER

collaborator

Texas Oncology Cancer Center

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER